CtDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: Turning hope into reality

M. Salati, K. Venetis, M. Fassan, U. Malapelle, F. Pagni, E. Sajjadi, N. Fusco, M. Ghidini

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)4607-4618
Number of pages12
JournalFuture Oncology
Volume17
Issue number33
DOIs
Publication statusPublished - 2021

Keywords

  • biomarker
  • circulating tumor DNA
  • ctDNA
  • efficacy prediction
  • gastric cancer
  • gastroesophageal adenocarcinoma
  • liquid biopsy
  • minimal residual disease
  • precision medicine
  • prognosis
  • durvalumab
  • ticilimumab
  • trastuzumab
  • blood level
  • cancer immunotherapy
  • cancer prognosis
  • cancer survival
  • cancer therapy
  • clinical effectiveness
  • clinical practice
  • DNA determination
  • DNA isolation
  • esophagus cancer
  • gene frequency
  • genotype
  • human
  • molecular fingerprinting
  • nonhuman
  • overall survival
  • patient selection
  • personalized medicine
  • prediction
  • progression free survival
  • Review
  • stomach cancer
  • therapy resistance

Cite this